Callosal thickness profiles for prognosticating conversion from mild cognitive impairment to Alzheimer’s disease: A classification approach
Abstract
Alzheimer's disease (AD) is the most common form of dementia. Finding biomarkers to prognosticate transition from mild cognitive impairment (MCI) to AD is important to clinical medicine. Promising imaging biomarkers of AD conversion identified so far include atrophy of the cerebral cortex and subcortical gray matter nuclei.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 22, 2018
- Source ID
- 10.1002/brb3.1142
Entities
People
- Chris Adamson
- Gareth Ball
- Marc L Seal
- Mark Walterfang
- Richard Beare
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Eisai
- Eli Lilly and Company
- Florey Institute of Neuroscience and Mental Health
- GE HealthCare
- Health Research
- Hoffmann-La Roche
- Innogenetics
- Johnson & Johnson
- Merck & Co.
- Meso Scale Diagnostics (United States)
- Monash University
- Murdoch Children's Research Institute
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Novartis
- Perrigo Company Plc
- Pfizer
- Roche (United States)
- Royal Melbourne Hospital
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Melbourne
- University of Southern California